Zobraziť v EDS

Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality.

Uložené v:
Podrobná bibliografia
Názov: Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality.
Autori: Canelo-Aybar C; Iberoamerican Cochrane Center, Barcelona, Spain; Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain., Alonso-Coello P; Institut de Recerca Sant Pau (IR Sant Pau), Barcelona, Spain; CIBER Biomedical Research Center in Epidemiology and Public Health (CIBERESP), Health Institute Carlos III (ISCIII), Madrid, Spain. Electronic address: palonso@santpau.cat., Muratov S; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada., Tarride JE; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada., Dimitrova N; European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy; Public Health Officer, International Agency for Research on Cancer, Lyon, France., Giusti F; European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy., Borisch B; Institute of Global Health, University of Geneva, Geneva, Switzerland., Castells X; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain., Duffy SW; Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK., Fitzpatrick P; National Screening Service, Dublin, Ireland; UCD School of Public Health, Physiotherapy & Sports Science, Dublin, Ireland., Follmann M; German Cancer Society, Berlin, Germany., Giordano L; CPO-Piedmont - AOU Città della Salute e della Scienza, Torino, Italy., Hofvind S; Cancer Registry of Norway, Oslo, Norway., Lebeau A; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Private Group Practice for Pathology, Lübeck, Germany., Quinn C; St. Vincent's University Hospital, Dublin, Ireland; University College Dublin, Ireland., Torresin A; Department of Physics, Università Statale di Milano (UNIMI), Milan, Italy., Giorgi Rossi P; AUSL Reggio Emilia, IRCCS, Reggio Emilia, Italy., Schünemann H; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada., Nyström L; Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden., Broeders M; IQ Health Science department, Radboud University Medical Center, Nijmegen, the Netherlands; Dutch Expert Centre for Screening, Nijmegen, the Netherlands. Electronic address: mireille.broeders@radboudumc.nl.
Korporácia: ECIBC contributor group
Zdroj: Breast (Edinburgh, Scotland) [Breast] 2025 Dec; Vol. 84, pp. 104621. Date of Electronic Publication: 2025 Oct 24.
Spôsob vydávania: Journal Article
Jazyk: English
Informácie o časopise: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9213011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-3080 (Electronic) Linking ISSN: 09609776 NLM ISO Abbreviation: Breast Subsets: MEDLINE
Imprint Name(s): Publication: 2002- : Amsterdam : Elsevier
Original Publication: Edinburgh ; New York : Churchill Livingstone, c1992-
Výrazy zo slovníka MeSH: Breast Neoplasms*/mortality , Breast Neoplasms*/diagnosis , Early Detection of Cancer*/standards , Early Detection of Cancer*/statistics & numerical data , Quality Indicators, Health Care*/statistics & numerical data , Program Evaluation* , Mass Screening*/standards, Humans ; Female ; Middle Aged ; Cross-Sectional Studies ; Registries ; Europe/epidemiology ; Aged ; Incidence ; Pilot Projects
Abstrakt: Competing Interests: Declaration of competing interest Nadya Dimitrova was staff of the Joint Research Centre during the period of the study and coordinated a working group of experts which did the study. Stephen W. Duffy carries out occasional paid consultancy for the biotechnology company GRAIL and the pharmaceutical company Roche. The remaining authors declare that they have no conflict of interest.
Aim: Evaluation of a breast cancer (BC) screening programme is necessary to ensure its quality. Performance measurements might be prioritized considering the association with outcomes related to BC mortality. We piloted an approach to explore the association of selected performance measurements with incidence-based BC mortality (IBM).
Methods: We performed an ecological analysis of aggregated data from regional or national population-based cancer registries and BC screening programmes in Europe, using 13 performance indicators. We built a panel data (longitudinal cross-sectional) regression model to estimate the association between screening performance measurements and IBM rates.
Results: We included data of 9 programmes and registries from Italy, Spain, Norway, Ireland and the Czech Republic. The number of screening years included in the dataset ranged from 5 to 20 years. In adjusted panel analyses, higher screening coverage, breast cancer detection rates (BCDR prevalent and subsequent rounds), node-negative proportion, and episode sensitivity were associated with lower incidence-based mortality (IBM), whereas a higher interval cancer rate was associated with higher IBM. The association for recall rate in subsequent examinations was small and imprecise.
Conclusion: Our pilot approach suggests association of several performance indicators with IBM. These indicators were related to the implementation of the screening programme (screening coverage), sensitivity (BC detection rate), and efficiency (recall rate). Further studies with larger datasets and individual data may confirm these findings.
(Copyright © 2025. Published by Elsevier Ltd.)
Contributed Indexing: Investigator: M Autelitano; E Colzani; J Daneš; A Gräwingholt; L Ioannidou-Mouzaka; S Knox; M Langendam; H McGarrigle; E Pérez Gómez; R van Engen; S Warman; K Young; C van Landsveld-Verhoeven; E Ardanaz; N Ascunce; A Brustolin; K Clough; AC Fanetti; J Galceran; O Majek; L Mangone; R Marcos; G Sampietro; D Lerda; Z Saz-Parkinson; E Parmelli; GP Morgano; A Janusch-Roi
Keywords: Breast Neoplasms/diagnostic imaging∗; Early detection of Cancer∗/methods; Female; Mass screening/methods; Program evaluation; Quality indicators, health care/standards∗
Entry Date(s): Date Created: 20251107 Date Completed: 20251126 Latest Revision: 20251126
Update Code: 20251127
DOI: 10.1016/j.breast.2025.104621
PMID: 41202390
Databáza: MEDLINE
Popis
Abstrakt:Competing Interests: Declaration of competing interest Nadya Dimitrova was staff of the Joint Research Centre during the period of the study and coordinated a working group of experts which did the study. Stephen W. Duffy carries out occasional paid consultancy for the biotechnology company GRAIL and the pharmaceutical company Roche. The remaining authors declare that they have no conflict of interest.<br />Aim: Evaluation of a breast cancer (BC) screening programme is necessary to ensure its quality. Performance measurements might be prioritized considering the association with outcomes related to BC mortality. We piloted an approach to explore the association of selected performance measurements with incidence-based BC mortality (IBM).<br />Methods: We performed an ecological analysis of aggregated data from regional or national population-based cancer registries and BC screening programmes in Europe, using 13 performance indicators. We built a panel data (longitudinal cross-sectional) regression model to estimate the association between screening performance measurements and IBM rates.<br />Results: We included data of 9 programmes and registries from Italy, Spain, Norway, Ireland and the Czech Republic. The number of screening years included in the dataset ranged from 5 to 20 years. In adjusted panel analyses, higher screening coverage, breast cancer detection rates (BCDR prevalent and subsequent rounds), node-negative proportion, and episode sensitivity were associated with lower incidence-based mortality (IBM), whereas a higher interval cancer rate was associated with higher IBM. The association for recall rate in subsequent examinations was small and imprecise.<br />Conclusion: Our pilot approach suggests association of several performance indicators with IBM. These indicators were related to the implementation of the screening programme (screening coverage), sensitivity (BC detection rate), and efficiency (recall rate). Further studies with larger datasets and individual data may confirm these findings.<br /> (Copyright © 2025. Published by Elsevier Ltd.)
ISSN:1532-3080
DOI:10.1016/j.breast.2025.104621